Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Researchers examine which teens have emotional symptoms after concussion

After a concussion, teens who are sensitive to light or noise may be more likely to also have emotional symptoms such as anxiety, according to a study released today that will be presented at The Sports Concussion Conference in Chicago, July 11 to 13, 2014, hosted by the American Academy of Neurology, the world's leading authority on diagnosing and managing sports concussion.

11 Jul 2014

New paper states that doctors have ethical obligation to educate, protect athletes from concussion

The American Academy of Neurology (AAN), the largest professional association of neurologists and a leading authority on sports concussion, is releasing a new position paper that states doctors have an ethical obligation to educate and protect athletes from sports concussion and clear them to play only when the athlete is medically ready, standing firm against objections from players, parents or coaches.

10 Jul 2014

Scientists find a new strategy for brain cancer treatment

Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. T

9 Jul 2014

Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Lysosomes are subcellular organelles that are present in most cells, with the major exception of red blood cells.

8 Jul 2014

Perrigo receives final approval from FDA for congestion relief tablets

Perrigo Company today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil Congestion Relief Tablets, 200 mg/10 mg.

8 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Regular walking may ease Parkinson's symptoms

People with mild to moderate Parkinson's disease who regularly walk for exercise may improve their motor function, mood, tiredness, fitness and some aspects of thinking abilities, according to a study published in the July 2, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Jul 2014

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.

1 Jul 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)

30 Jun 2014

Researchers give new, unprecedented 3-D view of most important brain receptors

Researchers with Oregon Health & Science University's Vollum Institute have given science a new and unprecedented 3-D view of one of the most important receptors in the brain - a receptor that allows us to learn and remember, and whose dysfunction is involved in a wide range of neurological diseases and conditions, including Alzheimer's, Parkinson's, schizophrenia and depression.

28 Jun 2014

Veterans with traumatic brain injury more likely to develop dementia in later life

Older veterans who have experienced a traumatic brain injury (TBI) are 60 percent more likely to later develop dementia than veterans without TBI, according to a study published in the June 25, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

25 Jun 2014

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it.

24 Jun 2014

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.

23 Jun 2014

Perrigo, Catalent settle Proair HFA patent case with Teva

Perrigo Company plc and its partner, Catalent, announced today that they have settled their first to file Hatch Waxman litigation with Teva with respect to a generic version of Proair HFA.

21 Jun 2014

N.Y. lawmakers reach medical marijuana deal

The agreement would allow doctors to prescribe it for a half-dozen medical conditions, but some lawmakers say the deal was more limited than they had hoped.

21 Jun 2014

First Edition: June 20, 2014

Today's early morning highlights from the major news organizations, including reports about a new poll of showing a majority of those signing up for marketplace plans had been uninsured before and the Obama administration's decision to extend marriage benefits, including family leave, to same-sex couples.

20 Jun 2014

New research reveals gene's role in type 1 diabetes

New research describes details of how a diabetes-related gene functions on a biological pathway that affects the release of insulin. The study authors say that finding drugs that act on that pathway may eventually lead to a new treatment for type 1 diabetes.

20 Jun 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

People with muscle diseases may benefit more from group doctor visits

A new study suggests that people with muscle diseases such as muscular dystrophies may benefit more from group doctor visits than individual appointments. The study is published in the June 18, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Jun 2014